Abstract
Cardiovascular disease is the leading cause of death in the world. Dyslipidemia, manifested by elevated low-density lipoprotein cholesterol (LDL-C) levels, is central to the development and progression of atherosclerosis. Dyslipidemia has become a primary target of intervention in strategies for the prevention of cardiovascular events. Therapeutic lifestyle changes, such as increased physical activity, weight loss, smoking cessation, and adoption of a healthier diet, are effectively reducing cardiovascular risk in primary and secondary prevention. The combination therapy lowered LDL-C levels and achieved the LDL-C target in patients with high cardiovascular risk.
| Original language | English |
|---|---|
| Pages (from-to) | 659-660 |
| Number of pages | 2 |
| Journal | Clinical Therapeutics |
| Volume | 39 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 1 2017 |
Keywords
- cardiovascular risk
- dyslipidemia
- lipids
- statins
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Fingerprint Dive into the research topics of 'Lipid-lowering Therapy in Patients With High Cardiovascular Risk: Dose or Combination?'. Together they form a unique fingerprint.
Cite this
Roever, L., Biondi-Zoccai, G., & Rao, S. V. (2017). Lipid-lowering Therapy in Patients With High Cardiovascular Risk: Dose or Combination? Clinical Therapeutics, 39(3), 659-660. https://doi.org/10.1016/j.clinthera.2017.01.029